Next, they performed mass spectrometry sequencing on the immunoprecipitates from five of the anti–TIF1-γ–positive patients without cancer and identified 23 candidate autoantigens, subsequently validating 10 of these targets that were unique to DM patients as compared with healthy controls (6). Here, TRIM33 is linked to dermatomyositis.